0TDD Stock Price and Chart — LSE:0TDD

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

Key facts today

Novo Nordisk cut its 2025 sales growth forecast to 8-14% and operating profit to 10-16%, causing its stock to plunge over 25% in pre-market trading.

Novo Nordisk's new CEO is facing competitive challenges in the anti-obesity market, with concerns raised about rivals potentially overtaking the company.

Novo Nordisk's Wegovy now has a lower risk of major heart events, while Eli Lilly's Mounjaro shows heart benefits in a recent study, impacting market dynamics.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as 0TDD.